RxDoctor Payments Data

Ghijung Kim, NP

Adult Health · Austin, TXNPI 1023507100

Payments from drug & device makers

$6,941in general payments, 2019–2025

Across 187 payments — averaging $37.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Bayer$1K
  • Vifor Pharma, Inc.$1K
  • Aurinia Pharma U.S., Inc.$405
  • GSK$253
  • Novo Nordisk$224
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$6,89199%
  • Education$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,941 in reported general payments places this provider in the 90th percentile of 933 adult health providers in Texas.

See all adult health providers in Texas

Medicare billing

Part B allowed, 2024
$22,514
Medicare patients
93
Services billed
229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide53$165,976
AuryxiaFerric Citrate14$38,299
VeltassaPatiromer Calcium Sorbitex23$22,899
Lanthanum Carbonate15$21,224
LokelmaSodium Zirconium Cyclosilicate25$20,285
FarxigaDapagliflozin Propanediol26$16,518
Sevelamer Carbonate88$15,294
Midodrine Hcl39$2,184
Torsemide20$871
Nifedipine ErNifedipine29$696
Calcium Acetate11$392
Carvedilol35$273
Amlodipine Besylate44$227
Allopurinol33$207
Lisinopril28$191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$190$165,97653 claims
Akebia Therapeutics IncAuryxia$16$38,29914 claims
AstraZenecaLokelma, Farxiga$1,728$36,80351 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 933 adult health providers in Texas.

Other adult health in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →